Intrexon Corporation (XON) Given Daily Media Impact Score of 0.31

News stories about Intrexon Corporation (NYSE:XON) have trended positive this week, Alpha One reports. Alpha One, a division of Accern, rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Alpha One ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Intrexon Corporation earned a media sentiment score of 0.31 on Alpha One’s scale. Alpha One also assigned news articles about the biotechnology company an impact score of 66 out of 100, meaning that recent media coverage is likely to have an impact on the stock’s share price in the next few days.

These are some of the media stories that may have effected AlphaOne Sentiment’s analysis:

Insider Buying and Selling by Quarter for Intrexon Corporation (NYSE:XON)

Intrexon Corporation (NYSE:XON) traded down 1.14% during midday trading on Friday, reaching $22.56. The company had a trading volume of 2,218,777 shares. The firm’s market capitalization is $2.70 billion. Intrexon Corporation has a 12 month low of $18.41 and a 12 month high of $32.90. The firm’s 50-day moving average price is $22.25 and its 200 day moving average price is $22.94.

Intrexon Corporation (NYSE:XON) last issued its quarterly earnings results on Wednesday, May 10th. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by $0.04. The business had revenue of $53.70 million during the quarter, compared to analysts’ expectations of $49.08 million. Intrexon Corporation had a negative net margin of 76.32% and a negative return on equity of 21.19%. The company’s revenue for the quarter was up 23.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.55) EPS. Equities analysts anticipate that Intrexon Corporation will post ($0.92) earnings per share for the current fiscal year.

Several brokerages have recently issued reports on XON. BidaskClub upgraded Intrexon Corporation from a “strong sell” rating to a “sell” rating in a research note on Thursday. Zacks Investment Research upgraded Intrexon Corporation from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research note on Tuesday, May 2nd. Stifel Nicolaus reiterated a “buy” rating and issued a $57.00 price objective on shares of Intrexon Corporation in a research note on Tuesday, April 4th. Finally, Wunderlich decreased their price objective on Intrexon Corporation from $50.00 to $35.00 and set a “buy” rating for the company in a research note on Tuesday, March 14th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $40.96.

COPYRIGHT VIOLATION WARNING: “Intrexon Corporation (XON) Given Daily Media Impact Score of 0.31” was first reported by Markets Daily and is the property of of Markets Daily. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at

About Intrexon Corporation

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply